SUMMARY: Simon Anderson (22) combines advanced physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.
Simon Anderson is building an Independent Scholars major around disparities in health and healthcare that stem from broader issues of diversity, equity, and inclusion. His major emphasizes coursework in biology and the medical humanities. Simon is also pursuing a degree in Biotechnology, with minors in Honors Interdisciplinary Studies and Pre-Medicine. Simon is a prime example of a Biotech student at JMU--passionate, determined, engaged, and innovative, says Dr. Stephanie Stockwell, past director of the Biotechnology program. By combining a wide array of interests and talents, Simon is paving the way for a lifetime of success and positive impact.
Simon is a graduate of South County High School in Fairfax County, Virginia, where he completed a demanding set of AP courses that nurtured his passions for math, biology, and chemistry. He also participated in the Governors School for Medicine and Health Sciences at Virginia Commonwealth University in the summer of 2017. During this program he worked with other students to examine case studies from three perspectives: Person (in-person interviews with the patient), Scientist (lab tests and results), and Community (implications of the ailment for the surrounding people)before splitting into smaller groups and analyzing a case study from all three perspectives simultaneously. In the area I grew up in, sickness and injury were the main reasons people went to the hospital, not for treatments related to opioid abuse, Simon remembers. But I learned that opioid abuse was also becoming a huge problem. Later, at JMU, he learned about the importance of local and county remote access clinics. Its not just in cities where people lack healthcare services, says Simon. If youre in a rural area you may also not have access.
Simon took a Viral Discovery (ISAT 203) course with ISAT professor Dr. Louise Temple in his freshman semester. In that class, Simon had his first real encounter with laboratory research. Viral Discovery is an exploratory experiential science class designed for incoming freshmen. Students learn about the life cycle and ecology of viruses infecting bacteria, collect soil samples, and practice techniques for isolation and purification of viruses from the soil. Dr. Temple is an expert in bacterial pathogenesis and bacterial virus discovery and genomic analysis. Isolated viruses are visualized in her lab using electron microscopy, and the genomic material is isolated and prepared for nucleic acid sequencing. Dr. Temples class built confidence in my ability to assess a problem and come up with solutions in a setting where theres flexible structure and no right answer, Simon recalls. He wanted to keep on with the work he had invested in phages, and so joined Dr. Temples lab. Simon has learned a number of valuable techniques related to DNA isolation and annotation, and is writing a paper about phages.
More recently, Simon enrolled in Cancer Genetics (BIO 477) with Dr. Tim Bloss, associate professor of biology. The course is cross-listed as a graduate-level course (BIO 577). I really enjoyed learning about how cancer develops and progresses, he says. Learning about molecular malfunctions in cancer helps me think about how I might create and test treatments in the future. Simon notes that Dr. Bloss is gifted at explaining genetics to students at both a basic and advanced level.
Simon is also a teaching assistant for JMUs General Chemistry laboratory courses (CHEM 131L and CHEM 132L). The course is designed to acquaint students with basic procedures and techniques encountered in the chemical laboratory. The experiments illustrate these techniques and supplement lectures. Simon gives instruction to students and assists with in-class procedures. He also digitally comments on students lab plans, data, and reports. It was a difficult, hybrid year of lab instruction due to the COVID pandemic. At first professors filmed experiments in the lab themselves, and then trialed virtual lab simulation software. This spring, Simon and other assistants returned to the labs to teach students. Proper use of pipette filler bulbs is one lesson we teach, notes Simon, People seem to have a lot of trouble with them.
Simon joined Independent Scholars to extend and broaden his undergraduate education. He understood that medical schools want to see students prepare themselves with an education in both science and the humanities. Simon found the Medical Humanities minor in the JMU catalog, and realized that he might build a major around it. Simons major is entitled Social Responsibility in Healthcare. It combines physical science and competencies necessary to help people of different backgrounds, capacities, and beliefs.
I wanted to take more classes across a wider range of subjects, says Simon. The Independent Scholars major made it possible to take a bunch of science courses that built a broader base around medical humanities. Simon hopes that the Independent Scholars major will give him exposure to a little bit of everything:biology, chemistry, bioinformatics, sociology, anthropology, psychology, and philosophy. I am just beginning to realize the connections between everything, he says. I want to understand how my research into biology and chemistry intersects with disparities in healthcare and beyond.
Simon says he likes the Independent Scholars approach to learning: I develop my questions, and then look for courses and experiences that can help me answer those questions. I wanted something different, to choose an area of study where the questions arent well established, or the answers known. Simon has written about the complexities of healthcare for the Independent Scholars e-zine on multiple occasions. In his essays, Simon seeks answers to enduring questions: What does it mean to be a doctor in our globalized world? How do institutions treat people of different backgrounds differently? What is healthy, and who gets to decide what healthy is? What are the impacts of structural and institutional prejudices? he asks. Simon is currently studying and writing about how person-oriented perspectives characterized by a holistic approach to patient management that embraces the physical, psychological, and social aspects of health and disease are becoming essential to undergraduate pre-medical education. His essays may be accessed here.
Independent Scholars students complete a culminating capstone project. Simons project has implications for the mitigation of racial disparities in health. He notes that, despite having roughly equal rates of breast cancer as non-Hispanic white women, African-American women are 40% more likely to die from the disease than white women, experience the highest breast cancer mortality of any racial group, and have an increasing rate of incidence of breast cancer. African American women are also more likely to have hormone-dependent breast cancers, which are deadlier than hormone-independent tumors.
Researchers have shown that delivering the protein HES-1 to hormone-dependent breast cancers has the effect of decreasing a nuclear protein called PCNA (found in dividing cells), which inhibits proliferation of the tumor, explains Simon. Were attempting to show that oxidative stress will prompt production of the GFP encoded behind an hlh-29 promoter to increase green fluorescent protein expression in all cells. If Simons project can provide evidence that oxidative stress is capable of increasing cells levels of proteins like HES-1, then they will have also laid the groundwork for potential clinical applications. One such application could be the induction of localized oxidative stress in tumors in an attempt to stall their proliferation, which would provide other therapies with an opportunity to shrink and kill the cancer.
Simon was a member of JMUs Huber Residential Learning Community (RLC) for freshmen in 2018-2019. The Huber RLC (which no longer operates) required two classes, one in each of the students first semesters. These classes focused on how different fields of medicine coexist, and gave a place for analysis and discussion of the social determinants of health. In the second semester, each student was required to volunteer with health- and education-related services in Rockingham County and Harrisonburg. Simon volunteered with the Virginia Personal Responsibility Education Program Innovative Strategies (VPREIS) project through JMUs Institute for Innovation in Health and Human Services (IIHHS). His volunteer work included working through the units of VPREISs Vision of Youa program for teen sexual and social health education, currently being administered to at-risk youth as part of a randomized controlled study in decreasing teen pregnancy in Virginia. Simon also volunteered at the ECHO (Ecumenical Community Helping Others) food pantry in Springfield, Virginia during the COVID-19 pandemic.
In the summer of 2021, Simon participated in a virtual summer research internship with the Pediatric Oncology Branch of the National Cancer Institute. During the experience, he worked on three projects that identified novel potential molecular targets in neuroblastoma, devised assembly schemes for designing new chimeric antigen receptors, and reviewed transcripts, patient data, and trial design documents for new psychological health programs. He also attended daily interactive seminars on many topics, including pediatric bone and neural cancers, cancer predisposition syndromes, lab mouse genetics, translation of basic science into therapies, and patient advocacy. Outside of the POB, he participated in an immunotherapy journal club, and two workshops on health disparities and social injustice in health research.
Simon also nurtures interests in how things are made. He enjoys watching videos about how the Disney and Universal theme parks create their engineered attractions, and builds models of landmarks and machinery from around the world. In the summer of 2019, Simon taught LEGO Robotics classes to young people in the Fairfax Collegiate Summer Program, based in Herndon.
Visit link:
Health Disparities Research and Biotechnology - JMU - James Madison University
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Yahoo Finance - November 16th, 2024
- Department of Biotechnology Launches Webinar Series on Biomanufacturing and Biofoundry Initiative - IBG NEWS - November 16th, 2024
- Multimodal scanning of genetic variants with base and prime editing - Nature.com - November 16th, 2024
- NEW INITIATIVE BY THE ITALIAN EMBASSY IN WASHINGTON ON BIOTECHNOLOGY WITH THE MILKEN INSTITUTE AND LEADING RESEARCHERS AND INDUSTRY EXPERTS -... - November 16th, 2024
- Vir Biotechnology Announces Positive End-of-Treatment Results for Tobevibart and Elebsiran Combinations in Chronic Hepatitis B from the MARCH Study at... - November 16th, 2024
- Albany State offers new Master of Science in Integrated Biotechnology program - The Albany Herald - November 16th, 2024
- What's Going On With Liver Disease Focused Vir Biotechnology Stock Is Friday? - Benzinga - November 16th, 2024
- iNtRON Biotechnology (KOSDAQ:048530) Is In A Strong Position To Grow Its Business - Simply Wall St - November 16th, 2024
- PDS Biotechnology Highlights Clinical Progress and Q3 Results - TipRanks - November 16th, 2024
- We Think Puma Biotechnology's (NASDAQ:PBYI) Robust Earnings Are Conservative - Yahoo Finance - November 16th, 2024
- Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest - Simply Wall St - November 16th, 2024
- APHIS Announces Final Notice on Additional Exemptions for the Movement of Organisms Modified or Produced Through Genetic Engineering - USDA APHIS - November 16th, 2024
- Adaptimmune nears second approval for TCR-T therapy - European Biotechnology News - November 16th, 2024
- Lundbeck reports 18% revenue growth in third quarter - The Pharma Letter - November 16th, 2024
- BioNTech to boost oncology offering with buy of Biotheus - The Pharma Letter - November 16th, 2024
- Puma Biotechnology Third Quarter 2024 Earnings: Beats Expectations - Yahoo Finance - November 16th, 2024
- WPI Receives Federal Funding to Address Anticipated Demand for Biology and Biotechnology Professionals and Educators - WPI News - November 3rd, 2024
- Jonathan Dinman to Direct the Institute for Bioscience and Biotechnology Research - College of Computer, Mathematical, and Natural Sciences - November 3rd, 2024
- PDS Biotechnology Co. (NASDAQ:PDSB) Given Average Recommendation of "Buy" by Analysts - MarketBeat - November 3rd, 2024
- COP16, DSI mechanism for benefit sharing from the use of digital sequence information approved - Renewable Matter - November 3rd, 2024
- Artificial Intelligence in Biotechnology Market to Hit USD 7.75 Billion by 2029 with 19.1% CAGR | MarketsandMarkets - PR Newswire - November 3rd, 2024
- Axonis Therapeutics raises $115 million in Series A financing - The Pharma Letter - November 3rd, 2024
- Regeneron third-quarter 2024 earnings top expectations - The Pharma Letter - November 3rd, 2024
- AbbVie inks up to $1.4 billion deal with EvolveImmune - The Pharma Letter - November 3rd, 2024
- CEO and Chairman of the Executive Board - European Biotechnology News - November 3rd, 2024
- The transformative potential of biotechnology and AI in healthcare - The Armchair Trader - November 3rd, 2024
- U.S. Biotechnology And Pharmaceutical Services Outsourcing Market Size to Reach USD 16.68 Billion By 2033 - BioSpace - October 6th, 2024
- Vir Biotechnology, Inc. (NASDAQ:VIR) is largely controlled by institutional shareholders who own 53% of the company - Yahoo Finance - October 6th, 2024
- Resolution Therapeutics scores 63.5 million in series B round - The Pharma Letter - October 6th, 2024
- Wiregrass Institute for Biotechnology welcomes local military veteran from Southeast Health as its first computational biologist - AOL - October 6th, 2024
- Generating and characterizing a comprehensive panel of CHO cells glycosylation mutants for advancing glycobiology and biotechnology research -... - October 6th, 2024
- Sapience Therapeutics Announces Participation at the 4th Annual Needham Private Biotech Company Virtual 1x1 Forum - PR Newswire - October 6th, 2024
- Spyre Therapeutics lures Abivax exec to be its CMO - The Pharma Letter - October 6th, 2024
- Convergence is AIxBio: AI and the Bioeconomy - OODA Loop - October 6th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - ABC News - September 13th, 2024
- Researchers, media engage to educate farmers on biotechnology - University World News - September 13th, 2024
- Congress targets Chinese influence in health tech. It could come with tradeoffs - The Associated Press - September 13th, 2024
- Comer Delivers Remarks in Support of Bipartisan BIOSECURE Act - House Committee on Oversight and Reform | - September 13th, 2024
- Announcement of $2 Million for the University of Delaware to Advance Biotechnology - WGMD Radio - September 13th, 2024
- Thailand's Competitiveness Enhanced Through Advanced Biotechnology at Thailand LAB INTERNATIONAL 2024 - BSA bureau - September 13th, 2024
- Biotechnology company Amgen expands global reach with technology innovation center in Hyderabad, India - BioProcess Insider - September 13th, 2024
- Adam's Biotech Scorecard: Can iTeos and GSK solve TIGIT's troubles? - STAT - September 13th, 2024
- Cizzle Biotechnology Advancing Lung Cancer Detection from R&D to Application with Moffitt Cancer Centre (VIDEO) - DirectorsTalk Interviews - September 13th, 2024
- MAIA Biotechnology Announces Positive Survival Updates in Phase 2 Study of THIO in Non-Small Cell Lung Cancer - Business Wire - September 13th, 2024
- MAIA Biotechnology Advances with Clinical Trials and Partnerships - TipRanks - September 13th, 2024
- Viridian Therapeutics reports positive results for veligrotug - The Pharma Letter - September 13th, 2024
- Chinese biotech firms refute US bill, stressing they have no access to Americans personal data - Global Times - September 13th, 2024
- Vir Biotechnology Enhances Portfolio with Sanofi Deal and Executive Appointments - TipRanks - September 13th, 2024
- Tesla BioHealing and Cell Biotechnology Partner to Advance Stem Cell Therapies - Vancity Buzz - September 13th, 2024
- Time to leverage intellectual property to drive innovation in seed and biotechnology sectors: Experts - The Times of India - May 5th, 2024
- Where Does Capricor Therapeutics Inc (CAPR) Stock Fall in the Biotechnology Field After It Has Risen 24.73% This Week? - InvestorsObserver - March 10th, 2024
- Where Does SpringWorks Therapeutics Inc (SWTX) Stock Fall in the Biotechnology Field After It Has Gained 12.41% This Week? - InvestorsObserver - February 18th, 2024
- Should Biotechnology Stock Axsome Therapeutics Inc (AXSM) Be in Your Portfolio Wednesday? - InvestorsObserver - February 18th, 2024
- Where Does Candel Therapeutics Inc (CADL) Stock Fall in the Biotechnology Field After It Has Gained 22.38% This Week? - InvestorsObserver - February 18th, 2024
- What is Biotechnology? Types and Applications - Iberdrola - January 25th, 2024
- Where Does Immunitybio Inc (IBRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.32% This Week? - InvestorsObserver - January 25th, 2024
- Can Sana Biotechnology Inc (SANA) Stock Rise to the Top of Healthcare Sector Monday? - InvestorsObserver - January 25th, 2024
- Should You Buy Sana Biotechnology Inc (SANA) Stock After it Has Fallen 15.41% in a Week? - InvestorsObserver - January 25th, 2024
- Where Does Tscan Therapeutics Inc (TCRX) Stock Fall in the Biotechnology Field After It Is Lower By -9.81% This Week? - InvestorsObserver - January 25th, 2024
- Should Biotechnology Stock Mink Therapeutics Inc (INKT) Be in Your Portfolio Monday? - InvestorsObserver - May 9th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Has Risen 22.18% This Week? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Dermata Therapeutics Inc (DRMA) Be in Your Portfolio Thursday? - InvestorsObserver - May 9th, 2023
- Should Biotechnology Stock Tempest Therapeutics Inc (TPST) Be in Your Portfolio Wednesday? - InvestorsObserver - May 9th, 2023
- Biotechnology - Applications of biotechnology | Britannica - May 1st, 2023
- Where Does BioLine RX Ltd - ADR (BLRX) Stock Fall in the Biotechnology Field After It Is Down -3.67% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Apellis Pharmaceuticals Inc (APLS) Stock Fall in the Biotechnology Field After It Is Higher By 4.17% This Week? - InvestorsObserver - May 1st, 2023
- Where Does Aldeyra Therapeutics Inc (ALDX) Stock Fall in the Biotechnology Field After It Is Lower By -11.45% This Week? - InvestorsObserver - May 1st, 2023
- Is Rain Oncology Inc (RAIN) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - April 7th, 2023
- Does Sana Biotechnology Inc (SANA) Have What it Takes to be in Your Portfolio Tuesday? - InvestorsObserver - April 7th, 2023
- Where Does Ambrx Biopharma Inc - ADR (AMAM) Stock Fall in the Biotechnology Field After It Is Lower By -15.43% This Week? - InvestorsObserver - April 7th, 2023
- Where Does Protagonist Therapeutics Inc (PTGX) Stock Fall in the Biotechnology Field After It Has Risen 3.62% This Week? - InvestorsObserver - April 7th, 2023
- What is Biotechnology? Definition, Types and Applications | TechTarget - March 21st, 2023
- Where Does Novavax Inc (NVAX) Stock Fall in the Biotechnology Field After It Is Lower By -12.99% This Week? - InvestorsObserver - March 21st, 2023
- Should Biotechnology Stock Outlook Therapeutics Inc (OTLK) Be in Your Portfolio Thursday? - InvestorsObserver - March 21st, 2023
- SANA BIOTECHNOLOGY, INC. : Results of Operations and Financial Condition, Financial Statements and Exhibits (form 8-K) - Marketscreener.com - March 21st, 2023
- Where Does Revance Therapeutics Inc (RVNC) Stock Fall in the Biotechnology Field After It Is Lower By -2.17% This Week? - InvestorsObserver - March 5th, 2023
- Is TG Therapeutics Inc common stock (TGTX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - March 5th, 2023
- Where Does GT Biopharma Inc (GTBP) Stock Fall in the Biotechnology Field After It Is Down -20.73% This Week? - InvestorsObserver - March 5th, 2023
- Where Does Dyne Therapeutics Inc (DYN) Stock Fall in the Biotechnology Field After It Is Lower By -2.35% This Week? - InvestorsObserver - March 5th, 2023
- Is CytomX Therapeutics Inc (CTMX) Stock at the Top of the Biotechnology Industry? - InvestorsObserver - November 17th, 2022